98%
921
2 minutes
20
Heterozygote GBA (glucosylceramidase beta) mutations increase the risk of Parkinson's disease (PD). Data based on the measured frequencies of GBA mutated alleles in the healthy population suggest that severe GBA mutations are associated with even higher risk for PD. These data, however, are prone to methodological biases resulting from the rarity of severe mutations and from ethnic-dependent differences in allele frequencies. To overcome these biases, we traced 13 Gaucher disease (GD) patients who were compound heterozygotes for one mild (N370S) and one severe GBA mutation and who reported a parent with PD. We determined the GBA mutation status of all parents and examined them whenever possible. While 50% of the parents carried a mild GBA mutation, we hypothesized that PD cases would be more likely to carry a severe mutation. We found that 10/13 PD parents had a severe mutation and only 3/10 carried a mild mutation (binomial test P<0.05). Using an unbiased methodology, we show that carriers of severe GBA mutations are at higher risk for PD relative to carriers of the mild mutations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bcmd.2016.11.007 | DOI Listing |
Front Neurol
August 2025
Medical Sciences Postgraduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Background: Autonomic symptoms are among the most important factors determining the quality of life in patients with Parkinson's disease (PD). This study aimed to assess the profile of autonomic dysfunction symptoms in three groups of patients with genetic PD, carrying mutations in , , and genes, compared with subjects with sporadic PD.
Methods: This case-control observational secondary analysis of prospectively collected data was performed on 742 patients (485 in the sporadic group, 165 in the LRRK2 group, 85 in the GBA group, and nine in the PRKN group).
J Neurochem
September 2025
Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center "Kurchatov Institute", Gatchina, Russian Federation.
Mutations in the GBA1 gene, encoding the lysosomal enzyme glucocerebrosidase (GCase), and the LRRK2 gene, encoding leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors for Parkinson's disease (PD). The potential use of LRRK2 inhibitors for treating not only LRRK2-associated PD (LRRK2-PD) but also GBA1-associated PD (GBA1-PD) is currently under discussion. In the present study, we aimed to evaluate whether LRRK2 inhibition affects lysosomal hydrolase enzymatic activities, autophagy, and alpha-synuclein levels in various cell types derived from LRRK2-PD and GBA1-PD patients, including macrophages derived from peripheral blood mononuclear cells (PBMC-derived macrophages), dopaminergic (DA) neurons derived from induced pluripotent stem cells (iPSC-derived DA neurons), and SH-SY5Y cells.
View Article and Find Full Text PDFMov Disord Clin Pract
August 2025
Department of Neuroscience "Rita Levi Montalcini", University of Turin, SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
Background: Postural abnormalities (PA) can complicate Parkinson's disease (PD). While age and motor severity are established predictors, the genetic role remains underexplored.
Objective: To evaluate the influence of major genetic variants on PA development in PD over 4 years.
Neurol Sci
August 2025
Neurology Clinic, University Clinical Center of Serbia, Dr Subotića 6, 11000, Belgrade, Serbia.
Objective: The GBA1 related Parkinson's disease (PD) is associated with more severe non-motor symptoms. To date, studies of the role of GBA1 mutations in the occurrence of impulse control behaviours (ICBs) in PD have yielded controversial results. Our aim was to investigate the frequency and characteristics of ICBs in PD patients with GBA1 mutations.
View Article and Find Full Text PDFTissue Barriers
August 2025
Department of Microbiology, TMMC&RC, Teerthanker Mahaveer University, Moradabad, India.
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by motor symptoms and progressive degeneration of dopaminergic neurons. Accumulating evidence indicates that mitochondrial dysfunction and oxidative stress are major contributors to PD pathogenesis.
Objectives: This review explores the molecular mechanisms underlying PD, emphasizing mitochondrial dysfunction and oxidative stress.